July 19, 2024


Paris-based Klineo has raised €2mn for its AI platform that facilitates access to cancer clinical trials.

Klineo’s platform connects doctors and patients directly with relevant clinical trials. It provides trial search, contact with medical centres, as well as real-time updates and notifications when a new clinical trial matches the patient’s criteria.

The startup’s solution currently covers trials on skin cancer, breast cancer, and lymphoma.

Klineo was founded in 2021 by oncologist Dr Arnaud Bayle and two engineers, Thomas Peyresblanques and Nicolas Drizard.

The <3 of EU tech

The latest rumblings from the EU tech scene, a story from our wise ol’ founder Boris, and some questionable AI art. It’s free, every week, in your inbox. Sign up now!

The startup aims to accelerate the inclusion of patients in clinical trials, which play a key role in introducing novel and potentially life-saving treatments, offering significant hope to individuals grappling with the illness.

“Today, too few patients benefit from a clinical trial because the search for one is a very tedious process,” Dr Arnaud Bayle said in a statement.

According to the Cancer Research Institute, less than 10% of cancer patients who are eligible for clinical trials participate in one. At the same time, approximately 20% of clinical trials fail because of insufficient participation.

“[Our] solution finally gives doctors and patients, wherever they are treated, the possibility of easily finding new therapeutic options adapted to each situation, and which ultimately enables medical research to progress,” Dr Bayle said.

Klineo will use the new funding to cover all types of cancer trials in France by the end of 2024, starting with lung cancer. The startup will also increase its team and improve its platform.

The French public investment bank BPI and a number of business angels participated in the round, which marked the company’s first fundraising attempt.

In the future, Klineo aims to expand its services beyond France and include trials for other illnesses, such as rare and neurological diseases.



Source link